Q-omics provides the consensus-scored POLD3 profile across patient tissues and cancer cell-line models. POLD3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, POLD3 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, POLD3 protein abundance shows 30,256 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where POLD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLD3 survival associations across molecular data types. POLD3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLD3 RNA expression–survival associations across cancer types. High POLD3 expression shows unfavorable associations in ACC, KICH, LGG, LIHC, KIRP and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for POLD3 RNA expression.
This table summarizes POLD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for POLD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLD3 shows lower tumor expression in KICH and KIRP and higher tumor expression in HNSC, STAD, LIHC and BLCA. The HNSC box plot shows higher POLD3 RNA expression in tumor versus normal tissue (log2 FC = +0.860, t-test p < 0.001).
This table shows molecular features associated with POLD3 in patient tissues and cancer cell lines. In patient samples, POLD3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
